Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance
about
RNase H activity: structure, specificity, and function in reverse transcriptionFrom the chemistry of epoxy-sugar nucleosides to the discovery of anti-HIV agent 4'-ethynylstavudine-FestinavirHIV-1 reverse transcriptionHIV-1 Reverse Transcriptase (RT) Polymorphism 172K Suppresses the Effect of Clinically Relevant Drug Resistance Mutations to Both Nucleoside and Non-nucleoside RT InhibitorsShould we include connection domain mutations of HIV-1 reverse transcriptase in HIV resistance testingN348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistanceConservation patterns of HIV-1 RT connection and RNase H domains: identification of new mutations in NRTI-treated patientsZidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptaseScreening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in ChinaLong-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimensTransmission patterns of HIV-subtypes A/AE versus B: inferring risk-behavior trends and treatment-efficacy limitations from viral genotypic data obtained prior to and during antiretroviral therapyA polymorphism at position 400 in the connection subdomain of HIV-1 reverse transcriptase affects sensitivity to NNRTIs and RNaseH activityCombinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.A novel molecular mechanism of dual resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors.Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations.Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.N348I in HIV-1 reverse transcriptase can counteract the nevirapine-mediated bias toward RNase H cleavage during plus-strand initiation.Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection.HIV-1 Ribonuclease H: Structure, Catalytic Mechanism and Inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.The "Connection" Between HIV Drug Resistance and RNase HThe N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excisionFailure of initial therapy with two nucleosides and efavirenz is not associated with early emergence of mutations in the C-terminus of HIV-1 reverse transcriptase.Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimensClinical management of HIV drug resistance.Mechanisms and factors that influence high frequency retroviral recombinationThe effects of RNase H inhibitors and nevirapine on the susceptibility of HIV-1 to AZT and 3TC.Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine.Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.Biochemical mechanism of HIV-1 resistance to rilpivirine.Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activityChanges in simian immunodeficiency virus reverse transcriptase alleles that appear during infection of macaques enhance infectivity and replication in CD4+ T cells.Dual-reporter phenotypic assay for human immunodeficiency viruses
P2860
Q24643032-4929F87E-10CA-424E-84DD-D16BD2C62AA7Q27010583-A872F33E-604E-4E61-8084-7435EF8803A5Q27023387-6B4806E9-6978-4D1E-9563-F81FE3B923E7Q27670634-23E3E39F-C956-4F78-802A-289A1DAEFAAEQ28471687-5D5D3C14-40A4-4F20-877D-8D8EE2E17062Q28471689-55942F41-576A-45BC-BEF8-24F52FAE712AQ28472255-E9AAECC1-38E7-4DC2-AD43-F6FB116AEB14Q28481004-D634DFD3-079E-40BA-8679-E0A8C2CA5F5DQ28485108-73A920C5-B963-4915-A346-95BDA7016528Q28485321-72E67721-AC11-4D11-A956-5B4873164940Q28487475-9C169698-A413-48AA-BC60-834F3154E76EQ28533996-9FF5F5F1-C6CD-4229-B17D-36552E481084Q33535654-CDECB45A-1D1E-4223-8307-541620BD4855Q33826904-BDE9F161-09AD-4028-9FFC-343EFC490517Q33877299-077F86A0-208E-4271-8993-0A161C56F54BQ33896402-60471B8F-9859-4F5E-82B5-12AAA9F8936DQ34038440-11E03A3D-3C62-44F1-87BF-AC6978C2945FQ34058254-11FFE1CC-1A94-4122-80E0-FAD5FEAF4936Q34059119-B073F6B4-FA9D-4A03-9CCF-B8624F520AEBQ34094395-6D3EF31C-EC78-4865-A009-CB2BBEAB0D9EQ34173947-8ADE89F1-5504-4ED9-AD41-FD44B2D1B864Q34223771-62242D33-2C84-4667-95D5-1552530DCF50Q34303603-500BE2DA-362B-4F35-8E42-5B974D5DB978Q34313605-54BCAAEA-C221-47B2-AA0A-DE2DE0A035E7Q34352431-41E00AE5-DF7A-4C39-B37A-C89601EF0D38Q34489239-3E6DD0F3-7F28-400C-B1ED-B0C53B9DABBBQ34681252-9436FD61-996C-4791-8AA6-00A5C72A573EQ34802871-464483AE-514D-4F16-A3B2-090D5FACABC8Q34916002-0784EA7D-9B9A-4747-9D89-E2DE06F0166EQ35004847-54D5F311-6420-4486-A4E6-BA943DAFB7FAQ35261045-042E34D1-E570-44DC-A8F6-7F091A7143C1Q35276750-E157100E-24B2-4ED5-B816-441934E44F32Q35684111-2B37F062-3C2D-4BC0-B6D0-8FB0999C3656Q35914346-11EB40E6-0D5E-4DF9-BA83-3E7E43BD4D65Q36295410-E966562A-31AC-4558-A70A-9EEEF2119738Q36347325-D488A3ED-CEC3-4638-A4A3-B2ED1175B04AQ36368294-23458194-27DE-47F9-93EE-AB166A9BC6C8Q36372693-227C3AAD-3033-4074-B74B-8E8B44CF22ABQ36376773-9BF67B31-2FCA-4CFB-916C-699D514A2E3CQ36452419-2FDD857D-25C3-473E-8060-E4E9228EE34C
P2860
Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@ast
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@en
type
label
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@ast
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@en
prefLabel
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@ast
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@en
P2093
P2860
P356
P1476
Mutations in the connection do ...... o-3'-deoxythymidine resistance
@en
P2093
Frank Maldarelli
Galina N Nikolenko
John M Coffin
Krista A Delviks-Frankenberry
Matthew J Fivash
Sarah Palmer
Vinay K Pathak
P2860
P304
P356
10.1073/PNAS.0609642104
P407
P577
2006-12-19T00:00:00Z